Revolutionizing hepatocellular carcinoma treatment: the advent of a new era of adjuvant therapy
Chinese Clinical Oncology · 2023-10 · 12 (5) · 49-49
DOI: 10.21037/cco-23-41 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Clinical Oncology, 2023-10. Verfasst von Joshua Sheng Hao Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore.
- Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore; Surgical Science Training Centre, Tan Tock Seng Hospital, Singapore, Singapore.
Zitieren
APA
Lim, J. S. H., & Shelat, V. G. (2023). Revolutionizing hepatocellular carcinoma treatment: the advent of a new era of adjuvant therapy. Chinese Clinical Oncology, 12(5), 49-49. https://doi.org/10.21037/cco-23-41
Vancouver
Lim JSH, Shelat VG. Revolutionizing hepatocellular carcinoma treatment: the advent of a new era of adjuvant therapy. Chinese Clinical Oncology. 2023;12(5):49-49. doi:10.21037/cco-23-41
BibTeX
@article{Lim2023,
author = {Lim, Joshua Sheng Hao and Shelat, Vishal G},
title = {Revolutionizing hepatocellular carcinoma treatment: the advent of a new era of adjuvant therapy},
journal = {Chinese Clinical Oncology},
year = {2023},
volume = {12},
number = {5},
pages = {49--49},
doi = {10.21037/cco-23-41}
}
EUVIMED